22 results about "BTLA" patented technology

The invention discloses an MUC1-CAR-T cell for co-expressing a BTLA / IL-18R chimeric receptor as well as a preparation method and application of the MUC1-CAR-T cell, and belongs to the technical field of biological medicines. The MUC1-CAR-T cell comprises a BTLA / IL-18R chimeric receptor and an MUC1-CAR structure, wherein the BTLA / IL-18R chimeric receptor is a BTLA MUC1 is used as a targeting molecule for CAR-T cell therapy, an extracellular domain of BTLA is connected with a transmembrane domain and an intracellular domain of an IL-18 receptor, and the co-expression BTLA / IL-18R chimeric receptor is designed. Experimental verification shows that the BTLA / IL-18R chimeric receptor can significantly improve the tumor killing ability of MUC1-CAR-T cells, can better inhibit the growth of tumors, and provides a novel immunotherapy strategy for the treatment of pancreatic cancer.

A BTLA-binding agent and immunoglobulin heavy chain and light chain polypeptides of the binding agent, as well as methods of using the BTLA-binding agent to treat a disorder or disease that is responsive to BTLA agonism, such as an autoimmune or inflammatory disease.

The invention discloses an amplification culture solution of TILs cells and a culture method thereof. The amplification culture solution comprises a complete culture medium, and an anti-BTLA antibody with the final concentration of 0.1-10 [mu] g / mL, penicillin with the final concentration of 50-500 [mu] g / mL, streptomycin with the final concentration of 50-500 [mu] g / mL, gentamicin with the final concentration of 10-100 [mu] g / mL and amphotericin with the final concentration of 1-50 [mu] g / mL are added into the complete culture medium. The anti-BTLA antibody component in the culture solution can relieve inhibition of BTLA on T cells by blocking combination of BTLA and a ligand HVEM of BTLA, so that the anti-tumor capability of TILs is enhanced; meanwhile, after the BTLA is combined with the ligand HVEM, T cell activation and proliferation can be inhibited, and rapid proliferation of TILs is promoted; the irradiation PBMC added in the TILs cell culture process can provide an activation signal for the TILs and drive rapid proliferation of the TILs cells.

The present invention provides isolated polypeptides capable of specifically binding to a protein target selected from LGALS9, CRP, BTLA, SAA, EGF, or FGA, or to a peptide thereof, especially under urinary conditions, which may be used for predicting in a urine sample of a subject suspected of having an infection whether the infection is a bacterial infection or a viral infection. The present invention further provides methods of diagnostics and treatment using the isolated polypeptides, and suitable diagnostic kits.

The present invention relates to anti-human BTLA agonist antibodies and their use for the prevention or treatment of inflammatory or autoimmune diseases or disorders such as systemic lupus erythematosus or graft versus host disease.

The invention provides application of a BTLA inhibitor in preparation of a medicine for preventing and / or treating chronic hepatitis B, and belongs to the technical field of biological medicine. Research finds that antagonistic B and T lymphocyte attenuation factors (BTLA) can promote removal of hepatitis B surface antigen (HBsAg), reduce the expression level of HBeAg, promote activation and proliferation of T cells and enhance host immune response, so that the purpose of preventing and / or treating chronic hepatitis B is achieved, and functional cure of chronic hepatitis B (CHB) is achieved. The invention provides more choices for medicines for clinically preventing and / or treating chronic hepatitis B.

The present invention provides a stable anti-BTLA (B and T lymphocyte attenuator) antibody pharmaceutical composition and its pharmaceutical use. The pharmaceutical composition comprises an anti-BTLA antibody, a buffer, and may further comprise at least one stabilizer and, optionally, a surfactant.

The present invention generally relates to antibodies or antigen-binding fragments that bind to human B and T lymphocyte attenuator (BTLA) and their uses. More specifically, the present invention relates to agonistic antibodies that bind to human BTLA and modulate its activity, and their use in treating inflammatory, autoimmune and proliferative diseases and disorders.

The application discloses a kind of MUC1-CAR-T cells of co-expression BTLA / IL-18R chimeric receptor and preparation method and application thereof, belong to the field of biological medicine technology.The MUC1-CAR-T cell includes BTLA / IL-18R chimeric receptor and MUC1-CAR structure;The present application uses MUC1 as the targeting molecule of CAR-T cell treatment, the extracellular segment of BTLA is connected with the transmembrane region and intracellular section region of IL-18 receptor, and designs co-expression BTLA / IL-18R chimeric receptor.Experiment verifies and finds that BTLA / IL-18R chimeric receptor can significantly improve the tumor killing ability of MUC1-CAR-T cell, can better inhibit the growth of tumor, provides a new immunotherapy strategy for the treatment of pancreatic cancer.

This invention provides novel and useful agents capable of modulating human B and T lymphocyte attenuation factors (BTLA). [Solution] The present invention generally relates to antibodies or antigen-binding fragments that bind to BTLA, and to the use thereof. More specifically, the present invention relates to agonist antibodies that bind to human BTLA and modulate its activity, and to the use thereof in treating inflammatory, autoimmune, and proliferative diseases and disorders.

The present invention relates to anti-BTLA antibodies. The present invention relates generally to antibodies or antigen-binding fragments that bind to human B and T lymphocyte attenuators (BTLAs) and uses thereof. More specifically, the present invention relates to agonistic antibodies that bind to and modulate the activity of human BTLA, and their use in the treatment of inflammatory, autoimmune and proliferative diseases and disorders.

The invention provides monoclonal antibodies and antigen-binding fragments thereof specific for BTLA, and methods of using the same to treat autoimmune disorder, including combination therapy.

Described herein are treatments and preventions for autoimmune disease or inflammatory disease using agonistic antibodies that bind to BTLA, and uses of an anti-BTLA antibody in the manufacture of a medicament for the treatment or prevention of an autoimmune disease or inflammatory disease. Also described herein are methods of agonizing BTLA activity without blocking or preventing the binding of HVEM to BTLA by administering an agonistic antibody that binds to BTLA.

The present application provides antibodies including antigen binding fragments thereof that specifically recognize B- and T-lymphocyte attenuator (BTLA). Also provided are methods of making and using these antibodies

The present invention relates to anti-human BTLA agonist antibodies and their use to prevent or treat inflammatory or autoimmune diseases or disorders, such as systemic lupus erythematosus or graft-versus-host disease.

The present application relates to the technical field of antibodies, in particular to anti-HVEM antibodies or fragments thereof and their uses. The technical problem solved by the present application is to provide a series of BTLA blocking anti-HVEM antibodies or fragments thereof. The anti-HVEM antibodies of the present application have good affinity, specificity and functional activity, can block the binding of BTLA to HVEM, promote the activation of T cells, and have application potential in cancer treatment.

The invention relates to an anti-BTLA nano antibody in the technical field of biological medicines. The amino acid sequence of the nano antibody is selected from one of SEQ ID No: 1, SEQ ID No: 2 or SEQ ID No: 3. The preparation method comprises three steps of BTLA antigen purification, phage display library panning and nano antibody expression purification, a high-purity antigen is obtained through secondary purification of Ni resin and an anion column, high-affinity clone is screened through four rounds of panning and ELISA verification, and a final product is high in purity and stable in yield. The nano antibody has the advantages of high specificity, high stability, excellent tissue penetrability and low-cost production, can efficiently block a BTLA-HVEM channel and activate T cell immune response, has a remarkable effect in treatment of tumors such as melanoma and lymphoma and rheumatoid arthritis, can be used as an ELISA or immunohistochemical reagent to detect the BTLA expression level, and has a wide application prospect. Important clinical application values and commercial prospects are realized.

This invention discloses the application of compound 1125-0440 in the preparation of BTLA inhibitors and lung cancer treatment drugs, belonging to the field of biomedicine. This invention discovers that compound 1125-0440 can bind to BTLA and inhibit its activity, thereby inhibiting BTLA transcription and expression, and suppressing the migration of lung cancer cells. This invention provides the pharmaceutical application of compound 1125-0440, offering a novel preventative and therapeutic drug for NSCLC or other BTLA-overexpressing tumors.

The application discloses an N-substituted 2-(2,5-dioxoimidazolidin-4-yl) acetamide compound and a synthesis method and application thereof, and belongs to the technical field of tumor immunotherapy drug development.The N-substituted 2-(2,5-dioxoimidazolidin-4-yl) acetamide compound disclosed by the application is a small-molecule ITIM motif inhibitor, the action mechanism of which is to combine with the ITIM motif of tyrosine phosphorylation in the tumor cell membrane, thereby blocking the combination of the ITIM of tyrosine phosphorylation and SH2, making SHP2 always in an inhibition state, simultaneously blocking multiple inhibitory receptor pathways including PECAM-1, PD-1, BTLA, KIR, CD3 and SIRP alpha, and finally improving the anti-tumor activity of immune cells.The experimental data show that the N-substituted 2-(2,5-dioxoimidazolidin-4-yl) acetamide compound can effectively enhance the killing of tumor cells by immune cells, inhibit the growth of tumors, and fully support the application of the compound in tumor immunotherapy.

The invention discloses an antibody that binds an extracellular part of human HVEM on human HVEM-expressing cells, that prevents binding of BTLA to HVEM when the antibody is bound to said extracellular part of HVEM, wherein said antibody displaces BTLA bound to said extracellular part of HVEM. The invention also discloses the use of such an antibody in combating certain diseases.

This invention provides an application of a reagent for detecting the expression level of lncRNA-NONHSAT178169.1, belonging to the field of biomedical technology. Research results showed significant differences in BTLA expression in peripheral blood T cells of CHB patients at different stages, with the highest expression in the IT phase, and CD8 expression... + T-cell differential expression was more pronounced. RNA-seq identified 29 differentially expressed lncRNAs, among which lncRNA-NONHSAT178169.1 was continuously downregulated under αBTLA treatment and validated by qPCR. Detection of lncRNA-NONHSAT178169.1 expression levels in test samples can specifically and sensitively predict or diagnose the immune tolerance phase of chronic hepatitis B. lncRNA-NONHSAT178169.1 provides more targets for predicting or diagnosing the immune tolerance phase of chronic hepatitis B.

This invention relates to the field of antibody technology, specifically to anti-HVEM antibodies or fragments thereof and their uses. The technical problem this invention aims to solve is to provide a series of BTLA-blocking anti-HVEM antibodies or fragments thereof. The anti-HVEM antibodies of this invention possess good affinity, specificity, and functional activity, can block the binding of BTLA to HVEM, promote T cell activation, and have potential applications in cancer treatment.